Reset filter
Trefwoorden
FDA第3相評価試験 ×
Meer tonen Trefwoorden
Inhoudsopgave
  1. 1. Klinische studie
  2. 2. Routinedocumentatie
  3. 3. Register-/kohortstudies
  4. 4. Kwaliteitswaarborging
  5. 5. Datastandaard
  6. 6. Patiëntenvragenlijst
  7. 7. Medisch vakgebied
    1. 7.1. Anesthesie
    1. 7.2. Dermatologie
    1. 7.3. HNO
    1. 7.4. Geriatrie
    1. 7.5. Gynaecologie/Ostetrie
    1. 7.6. Interne geneeskunde
      1. Hematologie
      1. Epidemiologie
      1. Cardiologie/Angiologie
      1. Pneumologie
      1. Gastro-enterologie
      1. Nefrologie
      1. Endocrinologie/Metabolisme
      1. Rheumatologie
    1. 7.7. Neurologie
    1. 7.8. Oogheelkunde
    1. 7.9. Palliatieve zorg
    1. 7.10. Pathologie/Forensische Geneeskunde
    1. 7.11. Kindergeneeskunde
    1. 7.12. Psychiatrie/Psychosomatisch
    1. 7.13. Radiologie
    1. 7.14. Chirurgie
      1. Algemene/maag-darm-chirurgie
      1. Neurochirurgie
      1. Plastische chirurgie
      1. Cardiothoracale chirurgie
      1. Traumachirurgie/Orthopedie
      1. Vaatchirurgie
    1. 7.15. Urologie
    1. 7.16. Tandheelkunde/MKG
Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

58 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

Nerventra Study Liver enzyme evaluation

- 08-06-16 - 1 Formulier, 2 Itemgroepen, 34 Data-elementen, 1 Taal
Itemgroepen: Demographic Information, Evaluation of liver enzymes
Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Eligibility Hepatocellular Carcinoma NCT02149771

- 20-09-21 - 1 Formulier, 2 Itemgroepen, 9 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Combination Treatment for Advanced Liver Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02149771

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis (GASTRIPEC) - Zytoreduktive Chirurgie / HIPEC Part 1

- 27-09-21 - 1 Formulier, 6 Itemgroepen, 75 Data-elementen, 1 Taal
Itemgroepen: Administrative Documentation, Physical Examination, Laboratory Data, Cytoreductive Surgery, Peritoneal Cancer Index, Type of surgery
Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction NCT-Identifier: NCT02158988 Source: Prof. Dr. med. Beate Rau, MBA Charité Universitätsmedizin Berlin Woche 12

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis (GASTRIPEC) - Zytoreduktive Chirurgie / HIPEC Part 2

- 02-09-21 - 1 Formulier, 7 Itemgroepen, 65 Data-elementen, 1 Taal
Itemgroepen: Administrative Documentation, Postoperative questions, Result of Surgery, Pathological tumor staging, Tumor staging, HIPEC, Administrative Documentation
Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction NCT-Identifier: NCT02158988 Source: Prof. Dr. med. Beate Rau, MBA Charité Universitätsmedizin Berlin Woche 12

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis (GASTRIPEC) - Unerrwünschtes Ereignis

- 21-11-17 - 1 Formulier, 3 Itemgroepen, 30 Data-elementen, 1 Taal
Itemgroepen: Administrative Documentation, Adverse Event, Administrative Documentation
Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction NCT-Identifier: NCT02158988 Source: Prof. Dr. med. Beate Rau, MBA Charité Universitätsmedizin Berlin Bitte faxen Sie die Seite umgehend an: Fax-Nr. 030 / 450 7 522 214

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis (GASTRIPEC) - Patientenrandomisation

- 21-11-17 - 1 Formulier, 4 Itemgroepen, 42 Data-elementen, 2 Talen
Itemgroepen: Administrative Documentation, Inclusion Criteria, Exclusion Criteria, Staging | stratification factors
Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction NCT-Identifier: NCT02158988 Source: Prof. Dr. med. Beate Rau, MBA Charité Universitätsmedizin Berlin Studien-Patientenidentifikation Bitte tragen Sie den Patienten in die Patientenidentifikationsliste (PIL) in Ihrem Investigator Site File (ISF) ein , um dem Patienten eine Pat-ID zuzuweisen. Bitte faxen Sie die Seiten R_01 und R_02 umgehend an die Studienzentrale der Charité : 030 – 450 7 522 214

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis (GASTRIPEC) - Hospitalisierung

- 21-11-17 - 1 Formulier, 2 Itemgroepen, 9 Data-elementen, 1 Taal
Itemgroepen: Administrative Documentation, Hospitalization
Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction NCT-Identifier: NCT02158988 Source: Prof. Dr. med. Beate Rau, MBA Charité Universitätsmedizin Berlin

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis (GASTRIPEC) - Chirurgische Sekundärintervention

- 21-11-17 - 1 Formulier, 2 Itemgroepen, 8 Data-elementen, 1 Taal
Itemgroepen: Administrative Documentation, Surgical intervention
Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction NCT-Identifier: NCT02158988 Source: Prof. Dr. med. Beate Rau, MBA Charité Universitätsmedizin Berlin Bitte nur chirurgische Sekundärinterventionen dokumentieren, die unmittelbar durch Tumorprogress bedingt sind.

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis (GASTRIPEC) - Progress

- 20-11-17 - 1 Formulier, 3 Itemgroepen, 16 Data-elementen, 1 Taal
Itemgroepen: Administrative Documentation, Progress, Administrative Documentation
Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction NCT-Identifier: NCT02158988 Source: Prof. Dr. med. Beate Rau, MBA Charité Universitätsmedizin Berlin Progress Hinweis: Bis Visit 10 (nach letztem Zyklus der Chemotherapie) bedeutet die Feststellung eines Progresses: Abbruch der Studientherapie: AS – Bogen ausfüllen Bei klinischem Tumorprogress (vor der OP - bis Woche 12) ist für diesen Patienten der Abbruch der Studientherapie zu beschließen. Patienten, die im Behandlungsarm B therapiert werden, soll die HIPEC ohne zytoreduktive Chirurgie (nach Ausschluss von Kontraindikationen) durchgeführt werden. Die Weiterbehandlung erfolgt nach Ermessen des behandelnden Arztes.

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis (GASTRIPEC) - Studienende

- 20-11-17 - 1 Formulier, 3 Itemgroepen, 15 Data-elementen, 1 Taal
Itemgroepen: Administrative Documentation, End of study, Administrative Documentation
Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction NCT-Identifier: NCT02158988 Source: Prof. Dr. med. Beate Rau, MBA Charité Universitätsmedizin Berlin Studienende Bitte füllen Sie diesen Bogen nur bei Studienende aus! Bitte faxen Sie diese Seite umgehend an die Studienzentrale Charité: 030 – 450 7 522 214 Hinweis: Ab dem oben angegebenen Datum ist keine weitere Dokumentation mehr erforderlich.

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis (GASTRIPEC) - Weitere Follow up

- 20-11-17 - 1 Formulier, 12 Itemgroepen, 40 Data-elementen, 2 Talen
Itemgroepen: Administrative Documentation, Physical Examination, Laboratory Data, Diagnostic procedures, Results, Concomitant therapy, Toxicities, Late toxicites, Progress, Adverse Event, Life quality, Administrative Documentation
Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction NCT-Identifier: NCT02158988 Source: Prof. Dr. med. Beate Rau, MBA Charité Universitätsmedizin Berlin Weitere Follow up (ab Monat 12 bis Studienende)

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis (GASTRIPEC) - 1. Follow up

- 20-11-17 - 1 Formulier, 9 Itemgroepen, 59 Data-elementen, 1 Taal
Itemgroepen: Administrative Documentation, Physical Examination, Laboratory Data, Diagnostic procedures, Results, Progress, Concomitant therapy, Adverse Event, Administrative Documentation
Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction NCT-Identifier: NCT02158988 Source: Prof. Dr. med. Beate Rau, MBA Charité Universitätsmedizin Berlin 1. Follow up (Monat 9)

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial